Filing identity and business context
Important metadata mismatch: The supplied filing is Isoray, Inc.’s Form 10-K for the fiscal year ended June 30, 2019, filed September 27, 2019. It is not a Perspective Therapeutics filing and does not report 2018 Q4. The filing describes Isoray’s development, manufacture and sale of Cesium-131 brachytherapy products; prostate cancer accounted for 89% of fiscal 2019 revenue.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise indicated.
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Net sales | $7.314 | $5.923 | +23% |
| Gross profit | $3.047 | $1.842 | +65% |
| Gross margin | 42% | 31% | +11 percentage points |
| Operating loss | $(5.254) | $(6.729) | Loss narrowed 22% |
| Net loss | $(5.144) | $(6.700) | Loss narrowed 23% |
| Basic and diluted loss per share | $(0.08) | $(0.12) | Improved |
| Cash used in operating activities | $(5.049) | $(5.712) | Use decreased |
At June 30, 2019, cash and cash equivalents were $5.326 million, working capital was $6.194 million, and the current ratio was 6.53. Total assets were $9.422 million and total liabilities were $1.742 million, including a $0.621 million asset retirement obligation. The balance sheet presents no interest-bearing borrowings. The company reported $181,000 of restricted cash and $530,000 of current inventory, plus $155,000 of non-current inventory.
Financing provided $7.374 million of cash in FY2019, principally from a registered direct offering. The company sold 11 million shares for $8.25 million gross proceeds in July 2018; year-end shares outstanding rose to 67.388 million from 56.331 million. The offering also included warrants, and 6.08 million common warrants were outstanding at year-end.
Changes versus the prior year
- Revenue rose 23%, driven mainly by prostate brachytherapy sales, which increased 27% to $6.488 million. Other sales were flat at $0.826 million.
- Gross margin improved from 31% to 42%, reflecting higher sales and lower isotope costs, partly offset by higher production labor and non-isotope materials costs.
- Operating expenses declined 3% to $8.301 million. Research and development expense, including collaboration costs, decreased as GT Medical Technologies assumed a greater share of GammaTile development costs and Isoray stopped sharing those costs when limited market release began.
- Net loss narrowed, but the company remained loss-making and continued to use substantial operating cash.
Outlook, management commentary and principal risks
- Management forecast FY2020 revenue growth of 20% and stated current cash was expected to cover projected operating cash needs for 18 months. It estimated cash-flow break-even in three to four years if revenue growth targets were achieved; these projections are not assured.
- The filing separately warns that, under its budget and revenue assumptions, additional capital may be needed within six to nine months to maintain the NYSE American listing. This differs from the 18-month operating-liquidity estimate and merits close review.
- GammaTile began limited market release in January 2019, but revenue from GT Medical Technologies was nominal. CMS denied GammaTile New Technology Add-on Payment status in August 2019; the filing says reimbursement remained available through the existing inpatient code and DRG mapping. A possible future NTAP application was discussed, with no assurance of approval.
- Isoray relied on Russian suppliers for all Cesium-131 beginning in FY2019 after ending its MURR supply arrangement; its supply contract ran through December 2020. Reactor outages, Russian geopolitical or sanctions-related disruption, and lack of domestic supply could interrupt production.
- Revenue was concentrated: three customers represented approximately 35.2% of FY2019 sales, and one physician practice/facility group represented 22.1%. Prostate products remained the core business in a competitive market affected by alternative treatments and reimbursement changes.
- The company elected not to renew its European Union CE Mark, citing limited sales and the cost of new clinical-trial requirements. This restricts its ability to sell in EU countries.
- Other commitments included $531,000 of operating lease payments, $164,000 of seed-core purchase obligations, and a $621,000 asset retirement obligation. No off-balance-sheet arrangements were reported. No material legal proceedings were disclosed in Item 3.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of June 30, 2019; the auditor did not provide an opinion on internal-control effectiveness.
Key facts investors should verify
- Confirm the intended issuer and period: the source is Isoray’s FY2019 10-K, not Perspective Therapeutics’ 2018 Q4 filing.
- Reconcile the stated 18-month operating cash runway with the warning that capital may be required within six to nine months to maintain the exchange listing; review subsequent financing and listing status.
- Track actual FY2020 revenue growth, cash burn and progress toward management’s break-even assumptions.
- Verify Cesium-131 supply continuity, contract terms and contingency arrangements given dependence on Russian sources.
- Monitor GammaTile adoption, revenue, hospital reimbursement and any renewed NTAP application following CMS’s denial.
- Assess customer concentration, potential share dilution from outstanding warrants or future equity raises, and the effect of reimbursement changes on product demand and margins.